Sitemap > Breaking Research > Infectious Diseases
Displaying 1151 - 1200 of 4290 results
- Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus infection in mice.
- Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes.
- High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma.
- Suppression of experimental autoimmune encephalomyelitis by extracellular adherence protein of Staphylococcus aureus.
- Mitigation strategies for pandemic influenza in the United States.
- Ligand-induced and nonfusogenic dissolution of a viral membrane.
- Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection.
- Duration and intensity of NF-kappaB activity determine the severity of endotoxin-induced acute lung injury.
- Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis.
- Antibody to hepatitis B core antigen is associated with the development of hepatocellular carcinoma in hepatitis C virus-infected persons: a 12-year prospective study.
- Use of semiconductor-based oligonucleotide microarrays for influenza a virus subtype identification and sequencing.
- Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay.
- Use of TaqMan real-time reverse transcription-PCR for rapid detection, quantification, and typing of norovirus.
- Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.
- The Wingless homolog WNT5A and its receptor Frizzled-5 regulate inflammatory responses of human mononuclear cells induced by microbial stimulation.
- Cardiovascular protective role for activated protein C during endotoxemia in rats.
- Flexible synthesis and biological evaluation of novel 5-deoxyadenophorine analogues.
- Synthesis and antibacterial activity of substituted flavones, 4-thioflavones and 4-iminoflavones.
- Evaluation of mismatch-binding ligands as inhibitors for Rev-RRE interaction.
- Hepatitis C virus entry: potential receptors and their biological functions.
- Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial.
- Effects of dexamethasone and L-canavanine on the intracellular calcium-contraction relation of the rat tail artery during septic shock.
- A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication.
- Antiviral drug discovery targeting to viral proteases.
- Understanding helicases as a means of virus control.
- Antiviral therapy targeting viral polymerase.
- Recent advances in antiviral agents: antiviral drug discovery for hepatitis viruses.
- Current status of anti-picornavirus therapies.
- New strategies for immune-mediated anti-viral drug and vaccine development.
- Matrix metalloproteinase inhibitors as prospective agents for the prevention and treatment of cardiovascular and neoplastic diseases.
- 48 weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection.
- Hepatitis C virus core protein inhibits tumor necrosis factor alpha-mediated apoptosis by a protective effect involving cellular FLICE inhibitory protein.
- Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway.
- In vitro microbicidal activity of the nonnucleoside reverse transcriptase inhibitor (NNRTI) UC781 against NNRTI-resistant human immunodeficiency virus type 1.
- Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo.
- Molecular virology of hepatitis C virus (HCV): 2006 update.
- Epidemiology of hepatitis C virus (HCV) infection.
- The natural history of hepatitis C virus (HCV) infection.
- Hepatitis B virus (HBV) and hepatitis C virus (HCV) dual infection.
- Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity.
- Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents.
- Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile.
- A live, attenuated recombinant West Nile virus vaccine.
- Microglial cells initiate vigorous yet non-protective immune responses during HSV-1 brain infection.
- Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.
- Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine.
- Modulation of the triggering receptor expressed on the myeloid cell type 1 pathway in murine septic shock.
- Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children.
- The anti-Candida vaccine based on the recombinant N-terminal domain of Als1p is broadly active against disseminated candidiasis.
- A fungicidal monoclonal antibody protects against murine invasive candidiasis.
< Previous 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 Next >